Guggenheim analyst Michael Schmidt raised the firm’s price target on Verastem (VSTM) to $14 from $13 and keeps a Buy rating on the shares. The firm is updating its model for Q4 results and increasing its adjusted peak U.S. estimates for LGSOC based on recent positive key opinion leader feedback on the upcoming launch, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem’s Promising Financial Outlook and Strategic Advancements Drive Buy Rating
- Verastem price target raised to $10 from $7 at H.C. Wainwright
- Verastem price target lowered to $14 from $16 at RBC Capital
- Verastem Unveils Strategic Plans in New Presentation
- Verastem files to sell 1.42M shares of common stock for holders